CompanyAKTXNasdaqTampa, FL

Akari Therapeutics Plc

Akari Therapeutics develops antibody drug conjugates targeting cancer.

SEC EDGAR ClinicalTrials.gov akaritx.com

DEF 14ASep 28Latest SEC filing

Aug 13Latest story

August 2026

Akari Therapeutics reports Q2 2026 results, keeps AKTX-101 Phase 1 on track for mid-2027

Aug 13Quarterly updateAkari Therapeutics Plc